Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
Psychedelic Therapy Begins in Colorado, Amid Tension Between Conservatives and Veterans
Colorado legalized psychedelic therapy, facing opposition in Colorado Springs. Veterans advocate for psilocybin to treat PTSD, despite conservative restrictions. Psilocybin therapy, legal in Colorado and Oregon, requires strict regulations and licensed facilitators. Concerns include high costs, FDA non-approval, and potential risks, but advocates see it as a valuable tool for mental health treatment.
2024 FDA Approvals
In 2024, the FDA approved 50 new drugs, focusing on cancer, with 15 approvals. Small molecules led with 32 approvals, followed by proteins and oligonucleotides. Notable approvals included a schizophrenia treatment and a NASH drug, marking significant advancements in therapeutic areas.
Four Clinical Trials We're Watching That Could Change Medicine in 2025
Recent clinical trials highlight advancements in medicine, including Ozempic and Wegovy's potential beyond weight loss, lenacapavir's HIV prevention, base editing for sickle cell disease, Pluvicto for prostate cancer, CBD for psychosis, and personalized breast cancer screening. These developments promise significant impacts on healthcare.
Related Clinical Trials:
RFK Jr. Says Drug Addicts Need Tough Love. Is He Right?
Robert F. Kennedy Jr.'s potential HHS role could significantly impact U.S. drug addiction policy, emphasizing tough love over harm reduction. His personal history with addiction informs his advocacy for therapeutic communities and drug courts, though his stance on anti-addiction medications remains unclear.
Encapsulating 2024 – Multidisciplinary Association for Psychedelic Studies
MAPS reflects on 2024's challenges, including FDA's call for more MDMA-assisted therapy research, and highlights accomplishments like supporting 7 psychedelic studies. Looking ahead to 2025, MAPS aims for transformative collaborations and advancing psychedelic policy reforms.
Colorado veterans and conservatives clash over psychedelic therapy
Colorado legalizes psychedelic therapy for conditions like PTSD, facing restrictions in conservative cities like Colorado Springs. Veterans advocate for access, highlighting its potential benefits despite ongoing debates and regulatory challenges.
2024 AIHP Year in Review
The article reflects on AIHP's 2024 achievements, including public engagements, research, and events on pharmacy history and ethics. Highlights include discussions on psychedelics, historical research, and educational initiatives. Looking ahead, AIHP plans to expand digital learning and collaborations, emphasizing the importance of community support for future endeavors.
Psychedelic therapy begins in Colorado, causing tension between conservatives and veterans
Colorado legalized psychedelic therapy, sparking debate in Colorado Springs where conservative leaders restrict it despite veterans' support. Psilocybin therapy, aimed at treating PTSD and depression, faces regulatory hurdles and concerns over its early-stage scientific validation and high costs.
Psychedelic treatment and mental health: Navigating a longer trip with optimism
Psychedelics disrupt neural pathways, enhancing brain plasticity and aiding in overcoming mental health conditions. They impair hippocampal episodic memory but enhance cortical familiarity memory. Psychedelics may reopen critical learning periods, promoting new behaviors, emphasizing the need for therapeutic guidance.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath